Latest Amgen Stories
OXFORD, England and SAN JOSE, May 7, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug
THOUSAND OAKS, Calif., May 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 39(th) Annual Healthcare Conference at 2:50 p.m.
CHICAGO, May 1, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog.
LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan MUMBAI and BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma
PARSIPPANY, N.J., April 18, 2014 /PRNewswire/ -- Daiichi Sankyo, Inc.
THOUSAND OAKS, Calif., April 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close
SANTA MONICA, Calif., April 11, 2014 /PRNewswire/ -- Kite Pharma, Inc.
THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.